주식회사온코빅스 / ONCOBIX
ONCOBIX's KOBDi Score is 46.04 as of Sep 2026, down 7.90 points since Apr 2025; it rose in 3 and fell in 4 of the 12 monthly updates. As of Sep 2026 it is ahead of about 63% of companies in its industry, against 63% in Aug 2026 and 50% in Apr 2025. Its strongest position was 63% (Sep 2026) and its weakest 38% (Aug 2025).
A year earlier, in Aug 2025, its score was 45.81 and it was ahead of about 38% of companies in its industry.
| Sep 2026 | 46.04 | ahead of 63% |
| Aug 2026 | 45.99 | ahead of 63% |
| Jul 2026 | 44.19 | ahead of 56% |
| Jun 2026 | 44.19 | ahead of 56% |
| May 2026 | 44.19 | ahead of 58% |
| Apr 2026 | 44.19 | ahead of 58% |
| Mar 2026 | 44.19 | ahead of 57% |
| Feb 2026 | 44.08 | ahead of 58% |
| Dec 2025 | 44.08 | ahead of 58% |
| Aug 2025 | 45.81 | ahead of 38% |
| Jul 2025 | 47.47 | ahead of 38% |
| May 2025 | 51.77 | ahead of 44% |
| Apr 2025 | 53.94 | ahead of 50% |
Where is ONCOBIX located?
ONCOBIX is registered at 경기도 용인시 기흥구 , South Korea (postal code 16950).
What industry is ONCOBIX in?
ONCOBIX belongs to Manufacturing › Pharmaceuticals & Biologics › Manufacturing of medicinal compounds and antibiotics.
How many employees does ONCOBIX have?
ONCOBIX has 5–9 employees.
What is ONCOBIX's KOBDi Score?
46.04 as of September 2026, ahead of about 63% of companies in its industry.
Who are ONCOBIX's competitors?
Similar companies include BioAssay, 동국제약주식회사 and Baozen.


